Abstract:BACKGROUND:Colorectal cancer (CRC) has become the second most deadly malignancy in the world, and the exploration of screening markers and precise therapeutic targets is urgent. Our previous research identified leukocyte immunoglobulin-like receptor B2 (LILRB2) protein as a characteristic protein of CRC, but the association between LILRB2 expression and clinicopathological features, the internal mechanism related to CRC progression, and screening diagnostic efficacy are not clear. Therefore, we hypothesized that LILRB2 is significantly highly expressed in CRC tissues, correlated with advanced stage and a poor prognosis, and could be used as a therapeutic target and potential screening biomarker for CRC.AIM:To explore whether LILRB2 can be used as a potential therapeutic target and noninvasive screening biomarker for CRC.METHODS:Patients who underwent radical surgery for CRC at China-Japan Friendship Hospital between February 2021 and October 2022 were included. Cancer and paracancerous tissues were collected to verify LILRB2 expression, and the association between LILRB2 expression and clinicopathological features was analysed. Serum was collected from CRC patients, adenoma patients and healthy controls during the same period to assess the diagnostic value of LILRB2 as a noninvasive screening biomarker, and its diagnostic value was further compared with that of the traditional markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).RESULTS:A total of 58 CRC patients were included, and LILRB2 protein was significantly overexpressed in cancer tissues compared with paracancerous tissues (P < 0.001). Angiopoietin-like protein 2 (ANGPTL2) protein, as the ligand of LILRB2, was synergistically overexpressed in CRC tissues (P < 0.001), and overexpression of LILRB2 and ANGPTL2 protein was significantly correlated with poor to moderate differentiation, vascular involvement, lymph node metastasis, distant metastasis, advanced tumor-node-metastasis stage and a poor prognosis (P < 0.05), which suggested that LILRB2 and ANGPTL2 are closely associated with CRC progression. In addition, serum LILRB2 concentrations increased stepwise in healthy individuals, adenoma patients and CRC patients with statistically significant differences. The sensitivity of serum LILRB2 for the diagnosis of CRC was 89.74%, the specificity was 88.89%, the area under the curve was 0.95, and the diagnostic efficacy was better than that of conventional CEA and CA19-9.CONCLUSION:LILRB2 protein can be used as a potential novel therapeutic target and noninvasive screening biomarker for CRC, which is beneficial for early screening and precise treatment.

Immune inhibitory receptor LILRB2 is critical for the endometrial cancer progression.

Inhibitory Leukocyte Immunoglobulin-Like Receptors in Cancer Development.

Abstract 5665: LILRB2 Mediates the Immune Escape of Breast Tumor Cells by Degrading HLA-A

Leukocyte Immunoglobulin-Like Receptor Subfamily B: Therapeutic Targets in Cancer

ANGPTL2/LILRB2 Signaling Promotes the Propagation of Lung Cancer Cells

LILRB1+ immune cell infiltration identifies immunosuppressive microenvironment and dismal outcomes of patients with ovarian cancer

LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

Expression of Survivin in Endometrial Cancer and Its Role in Regulating Apoptosis of Endometrial Cancer Cells

Low‐density lipoprotein receptor‐related protein 5/6 promotes endometrial cancer progression and cancer cell immune escape

LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer

Immunosuppressive Receptor LILRB1 Acts As a Potential Regulator in Hepatocellular Carcinoma by Integrating with SHP1

RBPJ Inhibits the Movability of Endometrial Carcinoma Cells by Mir-155/Nf-κb/ros Pathway

Effects of Immune Inhibitory Receptor LILRB2 on Proliferation and Apoptosis of Leukemia Cell Lines

Leukocyte Immunoglobulin-Like Receptor B2 Overexpression As a Promising Therapeutic Target and Noninvasive Screening Biomarker for Colorectal Cancer.

LRG1 is an Independent Prognostic Factor for Endometrial Carcinoma

Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia

Leukocyte immunoglobulin-like receptor B2: A promising biomarker for colorectal cancer

Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis